PDGFRB and acute lymphoblastic leukemia: Approximately 10–15% of children, adolescents, and young adults with Ph-like ALL have ABL class alterations (ABL1, ABL2, CSF1R, or PDGFRB) that are targetable with imatinib or dasatinib [6, 7].